INVISIBLE DISEASE Officially Recognized! Atezo Approval in ctDNA-Positive Bladder Cancer

IMvigor011 and the Birth of Modern Oncology’s “Invisible Disease” Revolution

Structure of the FDA’s 15 May 2026 approval

The approval announced by the FDA yesterday includes three simultaneous decisions:

An important clinical detail: patients whose Signatera test is negative do not receive treatment. Instead, serial testing continues within the 12-month monitoring window — if positivity is detected, treatment begins at that point. This turns the “wait and test” approach into an official clinical protocol. Patients experience some uncertainty before each test, but are protected from unnecessary exposure to immunotherapy and its side effects.

Monitoring 761 patients and randomizing 250 ctDNA+ patients

IMvigor011 (NCT04660344) is a multicenter, randomized, double-blind, placebo-controlled phase 3 study sponsored by Roche/Genentech. The lead author and principal investigator (PI), Professor Thomas Powles, is director of the Barts Cancer Centre at St. Bartholomew’s Hospital in London and a professor of genitourinary oncology. Powles is already recognized as one of the most prolific researchers in bladder cancer immunotherapy; he played a central role in KEYNOTE-045, JAVELIN Bladder 100 and EV-302.

The study’s clinical significance: 761 patients were systematically monitored. Of these, 250 (approximately 33%) became ctDNA-positive during follow-up — showing a sign of recurrence at the molecular level. These patients were randomized. The remaining 511 patients (67%) remained ctDNA-negative and stayed under surveillance without receiving any treatment. Thus, the study selected only patients who “might be helped” and gave treatment only to them. This is an excellent example of biomarker-guided clinical trial design .

Efficacy results

Let us unpack what these numbers mean. Patients in the placebo arm — those kept under surveillance despite testing ctDNA-positive — experienced radiological recurrence or died within a median of 4,8 months. This shows that ctDNA positivity is an aggressive prognostic marker : when tumor DNA is circulating in the blood, advanced-stage recurrence arrives within almost five months, even if imaging does not yet show disease.

Patients in the atezolizumab arm, by contrast, remained free of recurrence for a median of 9,9 months — approximately twice as long a DFS. More importantly, survival also increased: whereas the placebo arm lost half its patients by 21,1 months, the atezolizumab arm survived for 32,8 months. This represents an 11,7-month extension in median OS. An OS benefit of this magnitude is rare in adjuvant oncology.

Subgroup analyses — the pT2N0 surprise

Perhaps the study’s most surprising subgroup finding was that benefit was also observed in patients traditionally considered “low risk”: those with pT2N0 disease (node-negative, muscle-invasive but organ-confined) . Previous adjuvant immunotherapy studies (for example, CheckMate 274 with nivolumab) excluded these patients because they were considered to have “a prognosis probably too favorable to benefit from additional treatment”. Because IMvigor011 selected patients on the basis of ctDNA positivity, it also included pT2N0 patients; the result was benefit in this subgroup as well.

The conceptual significance of this finding is considerable: conventional surgical-pathological staging is less sensitive than the molecular risk assessment provided by ctDNA monitoring. A ctDNA-positive pT2N0 patient may have a much higher risk of recurrence than a ctDNA-negative pT3N1 patient. In Powles’s words at ESMO 2025: “ctDNA status enables risk stratification beyond conventional surgical-pathological staging."

Safety profile

The safety profile of adjuvant atezolizumab was consistent with that known from previous studies:

From a negative study to a positive paradigm

The story of IMvigor011 begins with an earlier disappointment, the IMvigor010 study. It was conducted in 2014-2018, and its results were published in 2021 by Bellmunt and his team (Lancet Oncology). The design was similar — adjuvant atezolizumab versus placebo in MIBC patients after radical cystectomy — but there was one critical difference: patient selection was based on conventional surgical-pathological characteristics (high-risk pT3-4 or pN+), rather than ctDNA.

The primary endpoint of IMvigor010 was DFS. The result: there was no significant benefit in the unselected population (HR 0,89; 95% CI 0,74-1,08). Many commentators concluded that “adjuvant immunotherapy does not work in bladder cancer”. Atezolizumab lost ground in this indication; as an alternative, nivolumab (CheckMate 274) showed benefit in a different population at high pathological risk and received FDA approval in 2021.

However, a retrospective analysis of IMvigor010 — a study published by Powles and his team in 2021 in Nature— revealed something major: ctDNA-positive patients had derived substantial benefit from atezolizumab (OS HR 0,59), whereas ctDNA-negative patients had not benefited (OS HR 1,38 — actually tending toward worse outcomes). This illustrated the problem of a mixed populationbehind conventional study results: the study was negative overall because it included patients who would not benefit from treatment (and might even be harmed); had we selected only the right patients, the signal would have been apparent.

The retrospective analysis of IMvigor010 generated the hypothesis for IMvigor011’s prospective design. Powles and his team made a bold proposal: “Instead of giving it to this entire population, let us give it only to those showing recurrence at the molecular level.” This hypothesis was launched prospectively in 2020; the results emerged in October 2025; yesterday, 15 May 2026, it became an FDA approval. A transition from a negative study to a positive paradigm within five years — an unusually rapid pace in modern oncology.

What is a tumor-informed, personalized ctDNA test?

Signatera, developed by Natera, is a tumor-informed ctDNA test (informed by the tumor). This is a different category from general cancer screening tests (such as Galleri) that may come to mind when someone mentions a “ctDNA test”. It works in the following sequence:

The strength of this approach is high specificity + high sensitivity. Because mutations specific to the patient’s own tumor are sought, incidental positivity (such as false positivity due to clonal hematopoiesis) is extremely rare. At the same time, even very small amounts of circulating tumor DNA fragments can be detected — estimated analytical sensitivity is at the level of one in a million (a ctDNA fraction as low as 0,01%).

Using this principle, Signatera had been used in the US under Medicare coverage for colorectal cancer MRD monitoring since 2020. The approval of 15 May 2026 marks the first time it has acquired FDA companion diagnostic status — meaning that the FDA has recognized it not only as a prognostic test, but also as a tool for clinical decision-making .

Why does this approval have “historic” significance?

This approval is a turning point for oncology practice in four respects:

What does this approval mean for Turkish patients?

The Signatera test is currently not widely used in routine clinical practice in Türkiye; however, a decision by the Republic of Türkiye Ministry of Health to reimburse this test under SGK coverage could come onto the agenda soon — particularly given the strength of clinical evidence generated by the FDA approval.

For centers providing international patient services, such as our Memorial Göztepe Cancer Center, this approval carries an important clinical message. MIBC patients from Kazakhstan, Uzbekistan, Azerbaijan, Russia, Ukraine and other countries may not have access to Signatera testing in their home countries; the option of obtaining this test in Istanbul and receiving adjuvant immunotherapy based on its result offers a clinical advantage. When preparing a tumor board report, this option should be specifically stated within the framework of “molecular residual disease monitoring + ctDNA-guided adjuvant immunotherapy”.

ctDNA-guided adjuvant immunotherapy: the outlook for 2026-2030

The approval of 15 May 2026 is not the end of a story for bladder cancer; rather, it is a door opening for other cancer types. Studies with parallel programs are currently underway:

These studies are expected to report within the next 2-3 years. If all are positive, ctDNA-guided adjuvant immunotherapy will become a standard tool in oncology practice by 2027-2028. This is the strongest structural tool for solving modern oncology’s “overtreatment problem” — namely, most patients receiving a treatment from which they will not benefit, while being exposed to toxicity.

This article is intended as medical news/information and does not provide individual treatment guidance. The FDA’s approval of atezolizumab + Signatera CDx on 15 May 2026 is significant for clinical practice in the US; it is not yet covered by SGK in Türkiye, where clinical use is privately funded. Although the ctDNA-guided adjuvant immunotherapy paradigm is expected to spread to other cancer types in the near future, the current approval applies only to muscle-invasive bladder cancer (MIBC). Individual treatment decisions should be made by the relevant medical oncology tumor board in light of the patient’s clinical characteristics and treatment options. All data cited in this article have been verified against the IMvigor011 (NCT04660344) publication by Powles et al. in NEJM in October 2025, the ESMO 2025 Berlin Presidential Symposium Abstract LBA8, the official FDA announcement of 15 May 2026 and the Roche press release of 20 October 2025. drozdogan.com has previously discussed ctDNA monitoring in the context of older patients with ER+ breast cancer; this article addresses the paradigm’s transition to its first FDA-approved treatment indication.